Compare Target Corporation (TGT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Tango Therapeutics Inc. — how do they compare? Target Corporation trades at $155.79 (market cap $69.05B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Target Corporation is far larger — about 18.4× Tango Therapeutics Inc.'s market cap, and Target Corporation pays a 3.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Tango Therapeutics Inc. for 0 Days on average.
| TGT | TNGX | |
|---|---|---|
Market Cap | $69.05B | $3.75B |
Volume | 3,728,482 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $32.90 |
52-Week Low | $83.68 | $7.50 |
Typical Hold Time | 137 Days | 0 Days |
Enterprise Value | $82.33B | $2.77B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target (TGT) trades at $155.30, up 1.13% today, with a neutral technical signal and key resistance at $155. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly earnings beats. Recent news highlights holiday price cuts to capture market share, while analyst consensus is evenly split between Buy and Hold ratings.
The outlook is balanced: valuation appears reasonable with a P/E of 15.77, and dividend stability offers income appeal, but competitive pressures and margin compression from aggressive pricing pose risks. Upside to the $166.95 consensus target depends on successful execution of growth initiatives amid a challenging retail environment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
